Expanded access frameworks for experimental treatments

Introduction

Expanded access refers to regulatory arrangements that allow patients with serious or life-threatening medical conditions to obtain experimental treatments that have not yet received marketing approval. These treatments may include investigational medicines, biological products, gene therapies and other advanced medical interventions.

Expanded access is particularly important when conventional treatment options have failed, are unsuitable or are unavailable. It provides a possible pathway for patients to receive promising experimental therapies outside ordinary clinical trials. However, experimental treatments may involve uncertain safety, effectiveness and long-term consequences.

Therefore, expanded access frameworks attempt to balance patient autonomy, medical necessity, scientific responsibility and regulatory supervision. They must ensure that compassionate treatment does not become an alternative to proper clinical testing or expose vulnerable patients to unreasonable risks.

Meaning and objectives of expanded access

Expanded access is a mechanism through which eligible patients receive investigational treatments before those products obtain full regulatory approval. It is also commonly described as compassionate use or special access.

Its principal objectives include:

Providing treatment opportunities to patients with serious diseases.

Supporting access where approved alternatives are unavailable.

Allowing carefully supervised use of promising experimental therapies.

Protecting patients through medical and ethical oversight.

Collecting relevant safety information where legally permitted.

Maintaining regulatory control over investigational products.

Expanded access does not establish a legal right to receive every experimental treatment. Availability depends on regulatory permission, medical justification, product supply and the willingness of the manufacturer or sponsor to provide the treatment.

Legal framework in India

1. New Drugs and Clinical Trials Rules, 2019

The New Drugs and Clinical Trials Rules, 2019, provide the principal regulatory framework for clinical trials and investigational new drugs in India.

The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), performs important regulatory functions under the applicable framework.

Rule 96 provides for compassionate use of an unapproved new drug in certain circumstances, subject to the prescribed conditions and regulatory requirements. The applicable provisions must be examined carefully to determine eligibility, permissions and oversight for the particular treatment.

Expanded access should not be confused with ordinary clinical trial participation. Clinical trials primarily evaluate safety and efficacy under a research protocol, whereas compassionate use focuses on providing treatment to eligible patients who may lack satisfactory alternatives.

2. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940, establishes the statutory framework for regulating the import, manufacture, distribution and sale of drugs in India.

Experimental treatments remain subject to applicable drug-control requirements. Their investigational status does not automatically exempt them from regulatory supervision.

3. National Ethical Guidelines for Biomedical and Health Research

The ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017, provide ethical principles for research involving human participants.

These guidelines emphasise informed consent, risk-benefit assessment, participant safety, confidentiality and independent Ethics Committee review. These principles are important when experimental treatments are provided through research-related or compassionate-use arrangements.

4. Medical ethics and professional responsibility

Medical practitioners must explain the experimental nature of a treatment, its known risks, uncertainties and available alternatives. They must avoid misleading patients through exaggerated claims of effectiveness.

The National Medical Commission's professional conduct framework and applicable medical regulations are relevant to the duties of treating doctors.

Major components of expanded access frameworks

1. Patient eligibility

Expanded access is generally intended for patients with serious or life-threatening conditions who have exhausted, cannot tolerate or cannot reasonably access satisfactory approved treatment options.

Eligibility should be based on medical evidence and an individual assessment rather than commercial considerations or public pressure.

2. Regulatory approval

The relevant regulatory authority must evaluate whether the proposed use satisfies applicable legal requirements. The assessment may consider the available safety information, scientific justification, proposed dosage, treatment monitoring and potential risks.

3. Informed consent

Patients must receive clear information explaining that the treatment is experimental and may not provide therapeutic benefit. They should also understand possible adverse effects, uncertainties and alternative treatment options.

Consent must be voluntary and obtained without coercion or misleading assurances.

4. Ethics Committee supervision

Independent ethical review helps ensure that expanded access arrangements protect patient welfare. Ethics Committees may examine the medical justification, consent documents, safety arrangements and potential conflicts of interest, depending on the applicable regulatory framework.

5. Manufacturer responsibilities

Manufacturers and sponsors may need to provide information about product quality, available safety evidence, storage requirements and treatment protocols. They may also have to maintain appropriate safety records and comply with applicable regulatory reporting obligations.

Important case laws

1. Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996)

The Supreme Court held that failure of government hospitals to provide timely medical treatment can violate Article 21. The judgment strengthens the constitutional importance of access to healthcare. However, it does not create an automatic right to receive an unapproved experimental treatment.

2. Parmanand Katara v. Union of India (1989)

The Supreme Court emphasised the importance of providing immediate medical assistance to preserve human life. Its reasoning supports the broader principle that medical systems must prioritise patient welfare, although it does not directly regulate compassionate access to investigational drugs.

3. Common Cause v. Union of India (2018)

The Supreme Court recognised the importance of dignity and individual autonomy in medical decision-making, particularly concerning end-of-life care and advance directives. The judgment is relevant to expanded access because treatment decisions must respect patient autonomy and informed preferences.

4. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court explained that valid medical consent must be voluntary and based on adequate information about the proposed treatment. This principle is particularly important when patients are considering experimental therapies involving uncertain outcomes.

5. Indian Medical Association v. V.P. Shantha (1995)

The Supreme Court recognised that paid medical services generally fall within the consumer protection framework, subject to the circumstances identified in the judgment. This decision is relevant to disputes involving medical negligence and deficiencies in healthcare services provided during experimental treatment.

These cases establish broader principles of healthcare access, consent, dignity and medical accountability. They do not directly create a comprehensive judicial framework for expanded access.

Challenges and safeguards

Expanded access creates several legal and ethical challenges. Patients suffering from serious illnesses may develop unrealistic expectations about experimental treatments. Pharmaceutical companies may also face difficulties concerning limited product supply, liability concerns and regulatory requirements.

Important safeguards include:

Independent medical assessment of patient eligibility.

Clear disclosure of experimental status and uncertainties.

Written informed consent.

Appropriate regulatory and ethical supervision.

Continuous monitoring of adverse events.

Transparent allocation of limited treatment supplies.

Protection against misleading commercial promotion.

Appropriate follow-up and medical support.

Another important concern is fairness. Access should not depend exclusively on a patient's financial position, social influence or ability to approach pharmaceutical companies.

International developments

The United States Food and Drug Administration operates expanded access programmes under its regulatory framework, including provisions under 21 CFR Part 312. These arrangements permit investigational drugs to be used outside clinical trials in qualifying circumstances.

The European Union also provides a compassionate-use framework under Article 83 of Regulation (EC) No. 726/2004. These international models demonstrate how regulatory authorities can facilitate access while maintaining patient-safety requirements.

Conclusion

Expanded access frameworks provide an important pathway for patients with serious medical conditions to obtain experimental treatments when satisfactory approved alternatives are unavailable. In India, the New Drugs and Clinical Trials Rules, 2019, together with the Drugs and Cosmetics Act, 1940, and applicable ethical guidelines, provide the regulatory foundation. Judicial decisions concerning healthcare access, informed consent and medical autonomy strengthen the principles governing these arrangements. An effective framework must ensure that compassionate access remains scientifically justified, ethically supervised, transparent and focused on patient welfare.